SciSparc (SPRC) announced Monday the publication of a European patent application that its collaboration partner Clearmind Medicine (CMND) submitted with the European Patent Office for a binge behavior psychedelic combination treatment.
The companies are researching combination treatments that integrate psychedelic molecules with the N-acylethanolamines family, SciSparc said.
Shares of SciSparc soared 188% and Clearmind Medicine rose 4% in premarket activity Monday.